The psoriasis area and severity index and alternative approaches for the assessment of severity: persisting areas of confusion by Kerkhof, P.C.M. van de
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25073
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
COHRHSPONDKNCK 1
References
1 Copeman PWM, Wilson Jones EW. Pigmented hairy epidermal 
nevus (Becker). Arch Dermatol 1965; 92: 2 4 9 -5 1 .
2 Glinick SE, Alper JC, Bogaars H, et a l  Becker’s melanosis: associated 
abnormalities, J Am Acad Dermatol 1983; 9: 509 -14 .
3 Jain HC, Fisher BK. Familial Becker’s nevus. Int J Dermatol 1989; 
28: 263-4 .
4 Fenselc NA, Donelan PA. Becker’s nevus coexistent with connective- 
tissue nevus. Arch Dermatol 1984; 120: 1347-50 .
5 Burgreen BL, Ackerman AB. Acneiform lesions in Becker’s nevus. 
Cutis 1978; 21: 6 1 7 -1 9 .
6 Wright RC. Another association with Becker’s nevus. Arch Dermatol 
1979: 115: 1035.
7 Bardaeh H. Perforating granulomatous folliculitis in Becker’s nevus. 
Arch Dermatol Res 19 79; 265: 4 9 -5 4 .
8 Fehr B, Panizsson RG, Schnyder UW. Becker’s nevus and malignant 
melanoma. Dermatologlca 1991; 182: 77 -80 ,
Tropaeolum nuijus and contact dermatitis
Sir, I read with interest the report by Derrick and Darley1 of a 
patient who developed a contact dermatitis to nasturtium. 
Nasturtium ( Tropaeolum majus) is not actually a member of the 
Cruciferae, but is in the Tropaeolaceae, a completely unrelated 
family of plants that originate principally from Central and 
South America. Plants of this family do indeed produce 
mustard oils with a characteristic peppery flavour, but they are 
not related botanically to the true mustard plants, which 
belong to the Cruciferae. The confusion is increased by the 
vernacular name nasturtium; used botanically, Nasturtium  
refers to a genus in the Cruciferae family which includes plants 
such as watercress.
The PASI score has persisted for 16 years as a handy
to
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where B =  erythema, I a lio  n,
A -  area. The various sites are h, head; i. trunk; u. upper 
extremities; I  lower extremities. A numerical value i.s given to
the extent of the lesions in these areas as follows: 1, < 10%; 
2, 10-30% ; 3, 50-50% ; 4. 50 -70% ; 5. 70 90%; ft, 
90-100% . I and I) are assessed according to a four-point 
scale: 0 =  no symptoms; 1, slight; 2, moderate; i, marked; and
4, very marked.
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body surface.7
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The Psoriasis Area and Severity Index and alternative 
approaches for the assessment of severity: persisting areas of 
confusion
Sir, Standardized procedures for medical technology assess­
ment are a sine qua non for communication of the results of 
existing and new treatments in dermatology. Important 
progress has been made with respect to new treatments for 
psoriasis. Calcipotriol, tacalcitol and cyclosporin have become 
available over the last decade and various new antipsoriatic 
drugs are being evaluated for their efficacy and side-effects. In 
1992, we reported on the limitations of the Psoriasis Area and 
Severity Index (PASI).1 However, the PASI remains the gold 
standard, a fossil tool of medical assessment.
In terms of quality of Hie, the post-treatment re
per His perhaps at least as relevant as the clearing capacity.
of established antipsoriatie treatments, it Is 
important to estimate disease activity in terms of quality of life. 
Finlay and co-workers proposed the ‘Sickness Impact Profile' 
and the ’Psoriasis 'X It Is of in teres
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significant correlation with these scores, 
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ation of a new therapy is carried out on 
many investigators in several centres.1
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antipsoriatic ellicacy and, registration, improvement
of psoriasis in terms of quality of life will be important. It is 
clear that the PASI will not be an adequate measure for 
dermatologists to use in the year 2000. This leaves us 2 years 
in which to develop a standardized approach within Europe to 
assess drug efficacy adequately. This approach must encom-
an assessment of the severity of psoriasis, using 
established quantitative procedures, and involve the develop­
ment of ‘Quality of Life’ scales. A joint venture between 
academic centres, the pharmaceutical industry and the officevS 
of the European Union, to develop a standard approach for 
evaluation of antipsoriatic treatment is needed.
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Manual of Cutaneous Laser Techniques. By T . S . A l s t e r  
(1997). ‘ Philadelphia: Lippincott-Raven. Pp. 190. ISBN
0-3975-8429-6. Price $90.
i
This short book costs about 50^ a page, but it is worth it. Dr 
Alsler writes with a determined practicality and clarity, with 
good advice on how to get started in laser work and on patient 
selection. There are individual chapters on the laser treatment 
of vascular lesions, tattoos and pigmented 
also a useful chapter on the laser management of scars,
’ acne scarring and striae, and one on skin 
resurfacing techniques which concentrates on tec 
using various types of CO.» laser. The book is very up-to-date 
and even contains accounts of laser-assisted hair removal, At 
the back of the book there is a very useful and up-to-date 
bibliography.
Medico-legal matters are obviously more pressing in 
practice in the United States than in the U.K., but Dr Alster 
is right to remind us about patient education and details her 
information sheets.
gist or plastichere for the derma
surgeon who wants to get started in dermatologica! laser 
therapy, and I hope the book will be updated on a regular 
basis.
I think the book could be strengthened with a chapter on 
laser safety and I was disappointed that there was no 
mention of the Erbium YAG laser, which appears to have 
a very significant place in for *1 /■* « / *
scarring; however, these are only minor criticisms and I can
thoroughly recommend this very easily readable addition to 
the dermatological laser literature.
J. A. Comma
The Role of the Laser in Dermatology: An Atlas. By T.Ousmiu) 
(1997). Chichester: J. Wiley and Sons. Pp. 272. ISBN 0-4719- 
6630-4. Price £150.00.
This volume is a companion textbook to Laser Treatment for Naevi 
by Dr Ohshiro; the latter provides more theoretical and
:mati«n concerning laser treatments, This 
current volume concentrates on the clinical applications of 
laser treatments in dermatology and is essentially an atlas with 
detailed accompanying case reports. It is suggested, in one of the 
forewords, that the plastic surgeon and laser 
armed with these two volumes will have all the
■m
on
atlas is
to base their laser treatment pr
into two chapters
one of which
extraordinary variety of lasers available in the Ohshiro Clinic; 
an extensive reference list which is grouped by subject matter 
rather than relating to the text; and a brief index. The first 
chapter concerns the background to laser therapy, including 
historical aspects of plastic surgery. The second chapter, 
which represents the vast majority of the book (220 pages), 
contains multiple case reports. These are divided into blood 
vessel anomaly group, melanin anomaly group, tumours, and
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